Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to -$56.6 million.

  • Compass Therapeutics' Net Income towards Common Stockholders fell 29.23% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 41.55%. This contributed to the annual value of -$56.6 million for FY2024, which is 33.25% down from last year.
  • Per Compass Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$56.6 million for FY2024, which was down 33.25% from -$42.5 million recorded in FY2023.
  • Compass Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$37,483 for FY2020, and its period low was -$82.2 million during FY2021.
  • Over the past 3 years, Compass Therapeutics' median Net Income towards Common Stockholders value was -$42.5 million (recorded in 2023), while the average stood at -$46.1 million.
  • As far as peak fluctuations go, Compass Therapeutics' Net Income towards Common Stockholders plummeted by 178.58% in 2021, and later spiked by 52.27% in 2022.
  • Yearly analysis of 5 years shows Compass Therapeutics' Net Income towards Common Stockholders stood at -$37,483 in 2020, then climbed by 15.09% to -$29.5 million in 2020, then plummeted by 178.58% to -$82.2 million in 2021, then surged by 52.27% to -$39.2 million in 2022, then fell by 8.33% to -$42.5 million in 2023, then plummeted by 33.25% to -$56.6 million in 2024.